ES2128055T3 - Vacuna contra infecciones de bacterias gram-negativas. - Google Patents

Vacuna contra infecciones de bacterias gram-negativas.

Info

Publication number
ES2128055T3
ES2128055T3 ES95917557T ES95917557T ES2128055T3 ES 2128055 T3 ES2128055 T3 ES 2128055T3 ES 95917557 T ES95917557 T ES 95917557T ES 95917557 T ES95917557 T ES 95917557T ES 2128055 T3 ES2128055 T3 ES 2128055T3
Authority
ES
Spain
Prior art keywords
gram
vaccine
lps
negative bacteria
against gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95917557T
Other languages
English (en)
Inventor
Apurba Bhattacharjee
Alan Cross
Erald Sadoff
Wendell Zollinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Army
Original Assignee
US Department of Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Army filed Critical US Department of Army
Application granted granted Critical
Publication of ES2128055T3 publication Critical patent/ES2128055T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/803—Antibody or antigen-binding fragment thereof that binds gram-negative bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Abstract

UNA VACUNA, EFECTIVA EN LA INDUCCION DE LA PRODUCCION DE ANTICUERPOS CON LOS QUE INMUNIZAR UN SEGUNDO SUJETO PASIVAMENTE CONTRA LA INFECCION POR BACTERIA GRAM-NEGATIVA Y PATOLOGIA EN LA QUE MEDIA LPS, COMPRENDE UN COMPLEJO POLIVALENTE NO COVALENTE FORMADO ENTRE LPS PURIFICADO, DESTOXIFICADO DERIVADO DE E. COLI Y PROTEINA DE MEMBRANA EXTERIOR PURIFICADA DERIVADA DE N. MENINGITIDIS. LA MISMA VACUNA TAMBIEN INMUNIZARA ACTIVAMENTE UN SUJETO HUESPED CONTRA LAS INFECCIONES BACTERIANAS GRAM-NEGATIVAS Y PATOLOGIA EN LA QUE MEDIA LPS. ENTRE ESTAS INFECCIONES BACTERIANAS GRAM-NEGATIVAS CONTRA LAS QUE PROTEGE LA VACUNA SE INCLUYEN INFECCIONES DE MENINGOCO.
ES95917557T 1994-04-20 1995-04-20 Vacuna contra infecciones de bacterias gram-negativas. Expired - Lifetime ES2128055T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23040294A 1994-04-20 1994-04-20

Publications (1)

Publication Number Publication Date
ES2128055T3 true ES2128055T3 (es) 1999-05-01

Family

ID=22865082

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95917557T Expired - Lifetime ES2128055T3 (es) 1994-04-20 1995-04-20 Vacuna contra infecciones de bacterias gram-negativas.

Country Status (9)

Country Link
US (3) US7025963B1 (es)
EP (1) EP0710118B1 (es)
AT (1) ATE173634T1 (es)
AU (1) AU2356095A (es)
DE (1) DE69506212T2 (es)
DK (1) DK0710118T3 (es)
ES (1) ES2128055T3 (es)
GR (1) GR3029477T3 (es)
WO (1) WO1995029662A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749831B1 (en) 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
EP1011440A4 (en) * 1997-05-16 2003-08-06 Medical Defense Tech Llc VACCINE AGAINST THE CORE OF LIPOPOLYSACCHARIDES
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
NZ508366A (en) 1998-05-01 2004-03-26 Chiron Corp Neisseria meningitidis antigens and compositions
WO1999061053A1 (en) 1998-05-29 1999-12-02 Chiron Corporation Combination meningitidis b/c vaccines
DK2270173T3 (en) 1999-05-19 2016-03-07 Glaxosmithkline Biolog Sa Neisserial combination compositions
MXPA02004283A (es) * 1999-10-29 2002-10-17 Chiron Spa Peptidos antigenicos neisseriales.
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DK1248647T3 (da) * 2000-01-17 2010-09-27 Novartis Vaccines & Diagnostic Ydre membranvesikel (OMV) vaccine omfattende N. meningitidis serogruppe B ydre membranproteiner
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US8828226B2 (en) 2003-03-01 2014-09-09 The Trustees Of Boston University System for assessing the efficacy of stored red blood cells using microvascular networks
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2007050606A2 (en) * 2005-10-24 2007-05-03 The University Of Maryland, Baltimore Detoxified endotoxin vaccine and adjuvant and uses thereof
US9616116B2 (en) * 2005-10-24 2017-04-11 University Of Maryland, Baltimore Detoxified endotoxin immunogenic compositions and uses thereof
WO2010027499A2 (en) * 2008-09-05 2010-03-11 University Of Massachusetts Medical School Methods, compositions and vaccines relating to neisseria meningitidis antibodies
US8258705B2 (en) * 2009-04-29 2012-09-04 Hubbell Incorporated Scotopically enhanced emergency light and control thereof
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
AU2010307084B2 (en) 2009-10-12 2015-12-17 Hemanext Inc. Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities
CA2781874A1 (en) 2009-10-12 2011-04-21 New Health Sciences, Inc. Oxygen depletion devices and methods for removing oxygen from red blood cells
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
ES2959120T3 (es) 2010-08-25 2024-02-20 Hemanext Inc Método para potenciar la calidad y la supervivencia de glóbulos rojos durante el almacenamiento
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
EP4218412A1 (en) 2010-11-05 2023-08-02 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
PT3061509T (pt) 2011-08-10 2019-09-10 New Health Sciences Inc Depleção de leucócito, oxigénio e/ou co2 integrada e dispositivo de filtro de separação de plasma
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN104602702B (zh) 2012-09-18 2021-08-27 葛兰素史密丝克莱恩生物有限公司 外膜囊泡
ES2900298T3 (es) 2013-02-28 2022-03-16 Hemanext Inc Dispositivo de agotamiento de gas para productos sanguíneos
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CA2978940C (en) 2015-03-10 2023-10-17 New Health Sciences, Inc. Oxygen reduction disposable kits, devices and methods of use thereof
KR102661405B1 (ko) 2015-04-23 2024-04-25 헤마넥스트 인코포레이티드 혐기성 혈액 저장 용기
BR122021024410B1 (pt) 2015-05-18 2022-05-03 Hemanext Inc Métodos para gerenciar um banco de sangue e para prover fornecimento de produtos de sangue total armazenados para medicina de transfusão
KR20190017747A (ko) 2016-05-27 2019-02-20 뉴 헬스 사이언시즈 인코포레이티드 혐기성 혈액 저장 및 병원체 불활성화 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB109688A (en) 1916-11-04 1917-09-27 Herbert Senior Vincent Improvements in Steam Jacketed Heating or Boiling Pans and like Receptacles.
EP0109688A3 (en) * 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
WO1987007148A1 (en) * 1986-05-23 1987-12-03 Midcon Labs, Inc. Co-vaccination using non-o-carbohydrate side-chain gram-negative bacteria preparation
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock

Also Published As

Publication number Publication date
US7235644B2 (en) 2007-06-26
WO1995029662A2 (en) 1995-11-09
ATE173634T1 (de) 1998-12-15
WO1995029662A3 (en) 1995-11-30
GR3029477T3 (en) 1999-05-28
AU2356095A (en) 1995-11-29
EP0710118B1 (en) 1998-11-25
DE69506212T2 (de) 1999-08-05
DE69506212D1 (de) 1999-01-07
DK0710118T3 (da) 1999-08-09
US7018636B1 (en) 2006-03-28
US20060159702A1 (en) 2006-07-20
EP0710118A1 (en) 1996-05-08
US7025963B1 (en) 2006-04-11

Similar Documents

Publication Publication Date Title
ES2128055T3 (es) Vacuna contra infecciones de bacterias gram-negativas.
GB9513074D0 (en) Novel anigen
Anwar et al. Outer membrane antigens of mucoid Pseudomonas aeruginosa isolated directly from the sputum of a cystic fibrosis patient
EA200100565A1 (ru) Новые стрептококковые антигены
EP1792994A3 (en) Vaccines of bacterial outer membrane vesicles
PT754050E (pt) Metodos e materiais contra bacterias gram-positivas
ATE279940T1 (de) Behandlung und prävention von helicobacter- infektionen
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
KR920703097A (ko) 스트렙토코커스 b군에 대한 백신 접합체
Anwar et al. Antibody response to acute Pseudomonas aeruginosa infection in a burn wound
Williams et al. Protein antigens of Staphylococcus epidermidis grown under iron-restricted conditions in human peritoneal dialysate
DK1135020T3 (da) Bipest-behandlinger
Ala'Aldeen et al. Immunogenicity and cross-reactivity of the 70-Kda iron-regulated protein of Neisseria meningitidis in man and animals
DK0776214T3 (da) Antibakterialt præparat indeholdende multimert alfa-lactalbumin
El-Shahawy et al. Peritoneal dialysis-associated peritonitis caused by Alcaligenes xylosoxidans
Tambawala et al. Continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis in a child: a rare case of peritonitis caused by sphingomonous paucimobilis
Barton et al. Further characterization of Renibacterium salmoninarum extracellular products
PT852497E (pt) Utilizacao de derivados de prostano e a sua combinacao com antibioticos no tratamento de infeccoes bacterianas
Lång et al. The maltose-inducible 43 kDa major outer membrane protein in Vibrio cholerae is immunogenic and common to different isolates
RU95120818A (ru) Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
Ludovici et al. Column chromatography and cell culture assay of Pseudomonas aeruginosa toxin Z preparations
Flancock The Role of the Cell Surface Components of Pseudomonas aeruginosain virulence
KILIAN 1. Bacterial interference with mucosal immunity
Baker Neutrophil bactericidal activity against Actinobacillus actinomycetemcomitans: The effects of antibiotics and the contribution of opsonins.
MOFFATT NEW PRINCIPLES IN BACTERIAL IMMUNITY pROFESSOR Georges Dreyer of the partment of Pathology, in the University of Oxford, has recently published (British Journal of Experi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 710118

Country of ref document: ES